Decoding Anthracycline- and Trastuzumab-Related Cardiac Dysfunction Prediction: HFA-ICOS Scores Versus Strain Imaging
ESC Heart Failure · 2025
DOI: 10.1002/ehf2.15399 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Hai Hoang Nguyen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Cardiovascular Care and Cardiovascular Imaging, Nhan dan Gia Dinh Hospital, Ho Chi Minh City, Vietnam. Hauptthemen laut MEDLINE: Trastuzumab, Anthracyclines, Breast Neoplasms, Stroke Volume. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Baseline Heart Failure Association–International Cardio-Oncology Society (HFA-ICOS) scores and serial left ventricular global longitudinal strain (LV-GLS) measurements have been found to be useful in predicting cancer therapy-related cardiac dysfunction (CTRCD). However, their integration for the purpose of improving prognostic accuracy remains unclear; and we aimed to develop a predictive model for CTRCD using baseline HFA-ICOS scores and the relative decline of LV-GLS in patients on anthracycline or trastuzumab.
Methods
We prospectively enrolled 443 chemotherapy-naïve women with breast cancer and cardiovascular risk factors, scheduled to receive anthracycline (n = 333) or trastuzumab (n = 110). Participants were stratified by the HFA-ICOS risk score. The left ventricular ejection fraction (LVEF) and LV-GLS were evaluated using echocardiography at baseline, before each treatment cycle, and every 3 months in the first year post-chemotherapy. CTRCD was a new LVEF reduction ≥10 percentage points to an LVEF < 50%, irrespective of symptoms.
Results
In terms of HFA-ICOS stratification, 258 patients (58.2%) were low risk, 180 (40.6%) were moderate risk and 5 (1.2%) were high risk. The proportions of low- and moderate-risk patients were similar in the anthracycline and trastuzumab groups. Twenty-four (7.2%) and seven (6.4%) patients treated with anthracycline and trastuzumab, respectively, displayed asymptomatic CTRCD. The addition of the baseline HFA-ICOS risk score did not improve the performance of the significant relative decline of LV-GLS > 15% in predicting both anthracycline [area under the receiver-operating characteristic curve (AUC) 0.93, 95% confidence interval (CI) 0.89–0.96, sensitivity 87.5%, specificity 93.2%] and trastuzumab (AUC 0.97, 95% CI 0.88–0.99, sensitivity 85.7%, specificity 93.2%)-related cardiac dysfunction.
Conclusions
Contemporary anthracycline and trastuzumab-based regimens resulted in similarly low incidences of CTRCD. In this context, LV-GLS evolution was the best predictor of CTRCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Intensive Cardiovascular Care and Cardiovascular Imaging, Nhan dan Gia Dinh Hospital, Ho Chi Minh City, Vietnam.
- Department of Internal Medicine, Faculty of Medicine, University of Health Sciences, Vietnam National University Ho Chi Minh City, Ho Chi Minh City, Vietnam.
- Department of Diagnostic Imaging, University Medical Center of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
- Heart Institute, Ho Chi Minh City, Vietnam.
- Vietnam National Heart Association, Ho Chi Minh City, Vietnam.
ORCID-Profile: Hai Hoang Nguyen, Nhat Minh Giang, Tri Huynh Quang Ho
Zitieren
APA
Nguyen, H. H., Giang, N. M., Vo, D. T., Ho, T. H. Q., & Ngoc-Hoa, C. (2025). Decoding Anthracycline- and Trastuzumab-Related Cardiac Dysfunction Prediction: HFA-ICOS Scores Versus Strain Imaging. ESC Heart Failure. https://doi.org/10.1002/ehf2.15399
Vancouver
Nguyen HH, Giang NM, Vo DT, Ho THQ, Ngoc-Hoa C. Decoding Anthracycline- and Trastuzumab-Related Cardiac Dysfunction Prediction: HFA-ICOS Scores Versus Strain Imaging. ESC Heart Failure. 2025. doi:10.1002/ehf2.15399
BibTeX
@article{Nguyen2025,
author = {Nguyen, Hai Hoang and Giang, Nhat Minh and Vo, Duc Tan and Ho, Tri Huynh Quang and Ngoc-Hoa, Chau},
title = {Decoding Anthracycline- and Trastuzumab-Related Cardiac Dysfunction Prediction: HFA-ICOS Scores Versus Strain Imaging},
journal = {ESC Heart Failure},
year = {2025},
doi = {10.1002/ehf2.15399}
}
EUVIMED